SCHEMBL3088034

SCHEMBL3088034

Cc1ccc(Cn2c(Cl)[c]c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 1/20 0.50
ALDH1A1 P00352 3/20 0.47
TP53 P04637 2/20 0.46
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.43
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.43
HTT P42858 2/20 0.43
HCRTR2 O43614 2/20 0.43
RECQL P46063 1/20 0.43
MAPK10 P53779 1/20 0.43
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.41
GALR3 O60755 1/20 0.41
NR2F2 P24468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15062740 0.87 TNF (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3073048 0.85 P2RX4 (0.51) P2RX4ALDH1A1TP53MEN1KMT2A
SCHEMBL3084692 0.84 ALOX5AP (0.45) ALDH1A1TP53GAASMN1; SMN2MAPT
SCHEMBL3097341 0.83 P2RX4 (0.54) P2RX4ALDH1A1TP53MEN1KMT2A
SCHEMBL3085744 0.83 DRD2 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2HCRTR2
SCHEMBL4383614 0.78 MEN1 (0.47) ALDH1A1TP53MEN1KMT2AGAA
SCHEMBL10399302 0.75 CYP19A1 (0.48) P2RX4ALDH1A1TP53MEN1KMT2A
SCHEMBL3093503 0.74 P2RX4 (0.40) P2RX4ALDH1A1TP53MEN1KMT2A
SCHEMBL3083770 0.74 TP53 (0.45) P2RX4TP53GAASMN1; SMN2MAPT
SCHEMBL30616068 0.72 P2RX4 (0.80) P2RX4ALDH1A1TP53GAARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR P2RX4 1442/4885ALDH1A1 1026/4885TP53 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.